Cerebrolysin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Cerebrolysin is a proteolytic protein indicated in the treatment of cerebrovascular disorders.

Generic Name
Cerebrolysin
DrugBank Accession Number
DB16599
Background

Not Available

Type
Biotech
Groups
Experimental
Synonyms
  • Cerebrolyzin
External IDs
  • FPE 1070
  • FPF 1070
  • FPF-1070
  • FPF1070

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Adjunct therapy in treatment ofAlzheimer's disease (ad)••••••••••••••••••••
Used as adjunct for symptomatic treatment ofCerebrovascular accident••••••••••••••••••••
Adjunct therapy in treatment ofCerebrovascular diseases••••••••••••••••••••
Adjunct therapy in treatment ofCraniocerebral trauma••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
37KZM6S21G
CAS number
12656-61-0

References

General References
  1. BASG: Ambotonin (Cerebrolysin) Intramuscular, Intravenous Injection [Link]
Wikipedia
Cerebrolysin

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedTreatmentCerebrolysin1somestatusstop reasonjust information to hide
4CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / Post-covid-19 Persistent Smell and Taste Disorders1somestatusstop reasonjust information to hide
4CompletedTreatmentIschemic Stroke1somestatusstop reasonjust information to hide
4CompletedTreatmentStroke1somestatusstop reasonjust information to hide
4CompletedTreatmentVascular Dementia (VaD)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution, concentrateParenteral215.2 mg/ml
SolutionIntramuscular; Intravenous215 mg/mL
SolutionIntravenous215.200 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at February 16, 2021 15:12 / Updated at July 18, 2023 22:58